HER2 Cancer Therapy Gets a Rethink With Immune System at the Center
New review reveals how HER2 reshapes the tumor immune environment — and why beating it requires more than blocking the oncogene.
Summary
HER2 is one of the most important cancer-driving proteins, found in breast, gastric, and other cancers. New research from Yale and Mass General reveals that HER2 does more than just fuel tumor growth — it actively suppresses the immune system by hiding cancer cells from immune detection, boosting immune checkpoint proteins, and releasing signals that dampen immune responses. This immune cloaking creates a major barrier to long-term treatment success. The review argues that truly effective HER2-targeted therapy must address this immune suppression, not just block the protein's growth signals. The authors outline emerging strategies combining HER2-targeted drugs with immunotherapy approaches to overcome this resistance, potentially transforming outcomes for patients with HER2-positive cancers across multiple tumor types.
Detailed Summary
HER2-positive cancers — including subtypes of breast, gastric, and colorectal cancer — have historically been treated by blocking the HER2 protein's growth-signaling activity. Drugs like trastuzumab and trastuzumab deruxtecan have improved survival, yet many patients eventually develop resistance or fail to achieve durable responses. A new expert review published in Cancer Cell argues the field has been underestimating a critical dimension of HER2 biology: its profound remodeling of the tumor immune microenvironment.
The review synthesizes current evidence showing that HER2 acts as an active suppressor of anti-tumor immunity. Specifically, HER2 signaling suppresses antigen presentation — the process by which cancer cells display markers that allow immune cells to recognize and attack them. It also upregulates immune checkpoint proteins, effectively applying the brakes to T-cell activity. Additionally, HER2 drives cytokine-mediated immunosuppression, flooding the tumor microenvironment with signals that inhibit immune function.
These immunomodulatory effects appear to be distinct from HER2's canonical role as a growth driver, meaning that even when oncogenic signaling is suppressed by targeted therapy, immune evasion mechanisms may persist. This creates an environment where residual or resistant tumor cells can survive and expand unchecked by the immune system.
The authors argue that next-generation HER2-targeting strategies must be designed with these immunological features in mind. This may include combinations of HER2-directed agents with checkpoint inhibitors, antibody-drug conjugates engineered to activate immune responses, or bispecific antibodies that simultaneously engage HER2 and immune effector cells.
The clinical implications are significant: understanding HER2's immune-suppressive role could guide smarter trial designs and combination regimens. Caveats include the review's reliance on existing literature rather than new primary data, and extensive author conflicts of interest with major pharmaceutical companies should be considered when interpreting the framing of treatment strategies.
Key Findings
- HER2 actively suppresses antigen presentation, hiding tumor cells from immune detection.
- HER2 upregulates checkpoint proteins, directly impairing T-cell killing of cancer cells.
- Cytokine-mediated immunosuppression driven by HER2 creates a broadly immune-resistant tumor environment.
- Effective HER2 therapy likely requires targeting immune suppression alongside oncogenic signaling.
- Combination strategies pairing HER2 agents with immunotherapy are identified as a priority direction.
Methodology
This is an expert review article synthesizing existing literature on HER2 biology, tumor immunology, and clinical trial data. No new primary experimental data were generated. The authors represent major academic cancer centers including Yale, Mass General Brigham, and the Broad Institute.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, which limits assessment of specific evidence cited and depth of mechanistic arguments. The review does not present new experimental data, relying on synthesis of existing literature. Multiple authors declare extensive financial relationships with pharmaceutical companies developing HER2-targeted and immunotherapy agents, introducing potential bias in framing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.